H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
TipRanks (Fri, 27-Dec 6:15 AM ET)
Assembly Bio spikes after early-stage data for Gilead-partnered Hep B therapy
Seeking Alpha News (Thu, 26-Dec 8:35 AM ET)
Globe Newswire (Thu, 26-Dec 8:00 AM ET)
Globe Newswire (Thu, 19-Dec 8:00 AM ET)
Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates
Globe Newswire (Thu, 7-Nov 4:05 PM ET)
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Assembly Biosciences trades on the NASDAQ stock market under the symbol ASMB.
As of December 30, 2024, ASMB stock price climbed to $15.40 with 48,379 million shares trading.
ASMB has a beta of 1.08, meaning it tends to be more sensitive to market movements. ASMB has a correlation of 0.06 to the broad based SPY ETF.
ASMB has a market cap of $97.89 million. This is considered a Micro Cap stock.
Last quarter Assembly Biosciences reported $7 million in Revenue and -$1.51 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.51.
In the last 3 years, ASMB traded as high as $29.40 and as low as $7.69.
The top ETF exchange traded funds that ASMB belongs to (by Net Assets): VTI, VXF, FESM, IWC, AVUV.
ASMB has outperformed the market in the last year with a price return of +57.7% while the SPY ETF gained +25.0%. However, in the short term, ASMB had mixed performance relative to the market. It has underperformed in the last 3 months, returning -2.5% vs +3.3% return in SPY. But in the last 2 weeks, ASMB shares have fared better than the market returning +0.1% compared to SPY -2.3%.
ASMB support price is $14.40 and resistance is $15.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASMB shares will trade within this expected range on the day.